Matthew L White1, Yan Zhang1, Syed A Jaffar Kazmi2, Michele Aizenberg3, Nicole Shonka4, Fang Yu5, Adams Kusi Appiah5. 1. Radiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America. 2. Anatomic Pathology, Geisinger Medical Center, Danville, Pennsylvania, United States of America. 3. Neurosurgery, the University of Nebraska Medical Center, Omaha, Nebraska, United States of America. 4. Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America. 5. Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Abstract
PURPOSE: Studies have evaluated the application of perfusion MR for predicting survival in patients with astrocytic brain tumors, but few of them statistically adjust their results to reflect the impact of the variability of treatment administered in the patients. Our aim was to analyze the association between the perfusion values and overall survival time, with adjustment for various clinical factors, including initial treatments and follow-up treatments. MATERIALS AND METHODS: This study consisted of 51 patients with astrocytic brain tumors who underwent perfusion-weighted MRI with MultiHance® at a dose of 0.1 mmol/kg prior to initial surgery. We measured the mean rCBV, the 5% & 10% maximum rCBV, and the variation of rCBV in the tumors. Comparisons were made between patients with and without 2-year survival using two-sample t-test or Wilcoxon rank-sum test for the continuous data, or chi-square and Fisher exact tests for categorical data. The multivariate cox-proportional hazard regression was fit to evaluate the association between rCBV and overall survival time, with adjustment for clinical factors. RESULTS: Patients who survived less than 2 years after diagnosis had a higher mean and maximum rCBV and a larger variation of rCBV. After adjusting for clinical factors including therapeutic measures, we found no significant association of overall survival time within 2 years with any of these rCBV values. CONCLUSIONS: Although patients who survived less than 2 years had a higher mean and maximum rCBV and a larger variation of rCBV, rCBV itself may not be used independently for predicting 2-year survival of patients with astrocytic brain tumors.
PURPOSE: Studies have evaluated the application of perfusion MR for predicting survival in patients with astrocytic brain tumors, but few of them statistically adjust their results to reflect the impact of the variability of treatment administered in the patients. Our aim was to analyze the association between the perfusion values and overall survival time, with adjustment for various clinical factors, including initial treatments and follow-up treatments. MATERIALS AND METHODS: This study consisted of 51 patients with astrocytic brain tumors who underwent perfusion-weighted MRI with MultiHance® at a dose of 0.1 mmol/kg prior to initial surgery. We measured the mean rCBV, the 5% & 10% maximum rCBV, and the variation of rCBV in the tumors. Comparisons were made between patients with and without 2-year survival using two-sample t-test or Wilcoxon rank-sum test for the continuous data, or chi-square and Fisher exact tests for categorical data. The multivariate cox-proportional hazard regression was fit to evaluate the association between rCBV and overall survival time, with adjustment for clinical factors. RESULTS:Patients who survived less than 2 years after diagnosis had a higher mean and maximum rCBV and a larger variation of rCBV. After adjusting for clinical factors including therapeutic measures, we found no significant association of overall survival time within 2 years with any of these rCBV values. CONCLUSIONS: Although patients who survived less than 2 years had a higher mean and maximum rCBV and a larger variation of rCBV, rCBV itself may not be used independently for predicting 2-year survival of patients with astrocytic brain tumors.
Authors: E A Knopp; S Cha; G Johnson; A Mazumdar; J G Golfinos; D Zagzag; D C Miller; P J Kelly; I I Kricheff Journal: Radiology Date: 1999-06 Impact factor: 11.105
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Ayca Akgoz; Rifaquat Rahman; Hui You; Jinrong Qu; Alhafidz Hamdan; Ravi T Seethamraju; Patrick Y Wen; Geoffrey S Young Journal: J Neurooncol Date: 2014-05-04 Impact factor: 4.130
Authors: T Hirai; R Murakami; H Nakamura; M Kitajima; H Fukuoka; A Sasao; M Akter; Y Hayashida; R Toya; N Oya; K Awai; K Iyama; J-i Kuratsu; Y Yamashita Journal: AJNR Am J Neuroradiol Date: 2008-06-12 Impact factor: 3.825
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556